Product Wiki · Recalls · Health Canada — Marketed Health Products

XARELTO (rivaroxaban) - Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement — recall 58819

Health Canada — Marketed Health Products · Canada · 2018-12-20

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Agency
Health Canada — Marketed Health Products
Recall identifier
58819
Date of alert
2018-12-20
Country / jurisdiction
Canada
Risk type
recall
Product category
Drugs
Product type
Marketed health products
Reported risk: Product safety
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/xarelto-rivaroxaban-increase-a

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

Related

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.